Given that PD1 is overexpressed not only on effector but also on regulatory tumor-infiltrating T lymphocytes [33], delivering a construct that suppresses the function of Tregs could be a potential strategy to reduce immunological tolerance to the tumor. The gene discussed is PDCD1; the disease is neoplasm.